Session Type: Abstract Submissions
Session Time: 5:30PM-7:00PM
Methods: Patients who completed the core study were allowed to continue into the extension study on the standard dosing regimen of 2 mg/kg subcutaneous CAN every 8 weeks or on last dose/dosing regimen received in the core study. Vaccination response was evaluated using post-vaccination antibody titers at 4 and 8 weeks after immunization. Patients were considered assessable for an antibody response to a specific vaccination if they had a measurement of antibody titer 0-14 days post-vaccination (pre-vaccination assessment) and at least 1 subsequent measurement of antibody titer at 4 weeks and/or 8 weeks post-vaccination. However, for patients with adequate pre-dose antibody titers and maintained during the trial, the specific patient vaccination was deemed non-assessable.
Results: During the extension phase, of 17 patients (≤6 years), 4 received 8 types of vaccinations against Corynebacterium diphtheria, Bordetella pertussis, Neisseria meningitidis, Clostridium tetani, influenza type A and type B, Haemophilus influenza B, Streptococcus pneumoniae, or hepatitis B. Of 20 unique patient-vaccination cases, 17 were assessable for a vaccination response, whereas for the remaining 3, pre-dose antibody titer was not available. For 16 (94.1%) assessable cases, post-vaccination antibody titers increased above protective levels. For one patient who received Tetravec formulation (diphtheria, tetanus and acellular pertussis combination), the response observed for 1 (vaccination against Clostridium tetani) of the 3 vaccines included in Tetravac represented optical density rather than antibody concentrations and hence considered non-evaluable. For 19/20 patient-vaccinations, including those without pre-dose antibody titers, protective levels were observed during the study, which were maintained throughout the extension.
Conclusion: Canakinumab appeared to have no effect on post-vaccination antibody production following the administration of non-live vaccines in CAPS patients.
1Brogan P, et al. Arthritis Rheumatol. 2015;67:(S10).
To cite this abstract in AMA style:Brogan P, Hofer M, Kuemmerle-Deschner JB, Lauwerys BR, Speziale A, Wei X, Laxer R. Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/effectiveness-of-childhood-vaccinations-in-caps-patients-treated-with-canakinumab-results-from-an-open-label-phase-iii-extension-study-2/. Accessed January 28, 2022.
« Back to 2017 Pediatric Rheumatology Symposium
ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-of-childhood-vaccinations-in-caps-patients-treated-with-canakinumab-results-from-an-open-label-phase-iii-extension-study-2/